OncoHost, a technology company focused on precision medicine, announced on Monday that the Business Intelligence Group has named OncoHost as a winner in the 2026 BIG Innovation Awards in the Health category.
Additionally, OncoHost was selected as a Top 10 Innovator – Small Business, reflecting the company's leadership in developing clinically impactful technologies.
OncoHost was recognised for its PROphet platform, an AI-driven plasma-proteomics solution designed to help oncologists predict clinical benefit and therapy-related toxicity from a single pre-treatment blood test. Its first commercial offering, PROphetNSCLC, guides first-line immunotherapy decision-making in metastatic non-small cell lung cancer (NSCLC) by revealing host-response insights that extend beyond tumour-only biomarkers.
The BIG Innovation Awards are designed to honour organisations, products, and leaders transforming industries through applied innovation, intelligent platforms, and measurable real-world impact.
Abbisko Therapeutics reports US FDA acceptance of pimicotinib NDA
Summit Therapeutics and GSK form collaboration to study ivonescimab combination therapy
Summit Therapeutics submits FDA application for ivonescimab in EGFR-mutated lung cancer
Acousia Therapeutics completes patient enrolment in Phase 2 trial of Bimokalner
ZYUS Life Sciences reports positive preliminary results from Phase 2a trial of Trichomylin softgel
DELFI Diagnostics names new chief financial officer
Arbele's ARB1002 receives US FDA Orphan Drug Designation
GSK reports positive phase III results for bepirovirsen in chronic hepatitis B
Day One completes Mersana acquisition to add rare cancer antibody drug conjugate
Cartography Biosciences partners with Pfizer to discover tumour-selective antigens
BostonGene and AstraZeneca collaborate to advance AI-driven oncology development
RedHill advances RHB-102 across GI indications
Kelun-Biotech lung cancer drug granted Breakthrough Therapy Designation in China